UNLIMITED TURBO SHORT - MODERNA | Market Closed - Borsa Italiana 16:04:59 2024-06-28 EDT | ||
| 7.42 EUR | +2.77% |
|
| Current month | +42.52% | ||
| 1 month | +75.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 7.34 | +1.66% |
| 24-06-27 | 7.22 | +1.69% |
| 24-06-26 | 7.1 | +25.44% |
| 24-06-25 | 5.66 | -1.05% |
| 24-06-24 | 5.72 | -5.61% |
Real-time Borsa Italiana
Last update June 28, 2024 at 04:04 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P23825 | |
| ISIN | NLBNPIT23825 |
| Date issued | 2024-05-24 |
| Strike | 188.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.45 € |
|---|---|
| Lowest since issue | 2.69 € |
| Spread | 0.05 € |
| Spread % | 0.67% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- P23825 Certificat
